OUTBACK: GOG 274 Study

OUTBACK: GOG 274 Study

Share this:

The Outback Trial: A phase III trial of adjuvant chemotherapy following chemoradiation as a primary treatment for locally advanced cervical cancer compared to chemoradiation alone.

PROTOCOL ID

GOG 274

PROTOCOL DESCRIPTION

The purpose of this study is to compare standard treatment, radiation therapy combined with the chemotherapy drug cisplatin (chemo-radiation), to standard chemo-radiation therapy plus additional experimental chemotherapy with FDA approved agents carboplatin and paclitaxel to see if it reduces the risk of tumor recurrence and improves overall survival.

ELIGIBILITY CRITERIA

Patients MUST:

  • Have locally advanced cervical cancer suitable for primary treatment with chemo-radiation with curative intent
  • Be 18 years of age or older
  • Be diagnosed with Stage IB2, II, IIIB, or IVA disease
  • Have a performance status of 0-2
  • Have Histological diagnosis of: squamous cell carcinoma, adenocarsinoma, or adenosquamous cell carcinoma of the cervix
  • Have Adequate renal function

Principal Investigator

Janet L. Osborne, M.D.

Contact Information

Vickie Yates, RN
Clinical Research Nurse Coordinator
Phone: 540-204-7635
Email: vlyates@carilionclinic.org